CIBC Asset Management’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$4.17M Buy
27,556
+1,292
+5% +$198K 0.01% 527
2025
Q4
$3.59M Buy
26,264
+275
+1% +$36K 0.01% 548
2025
Q3
$3.31M Buy
25,989
+8,682
+50% +$1.06M 0.01% 488
2025
Q2
$2.07M Buy
17,307
+921
+6% +$104K 0.01% 565
2025
Q1
$1.8M Sell
16,386
-2,723
-14% -$290K 0.01% 588
2024
Q4
$1.84M Buy
19,109
+20
+0.1% +$2.13K 0.01% 594
2024
Q3
$2.18M Sell
19,089
-5,194
-21% -$589K 0.01% 570
2024
Q2
$2.59M Buy
+24,283
New +$2.44M 0.01% 501
2022
Q2
Sell
-5,711
Closed -$501K 1412
2022
Q1
$501K Buy
+5,711
New +$494K ﹤0.01% 838
2021
Q2
Sell
-2,906
Closed -$249K 1383
2021
Q1
$249K Sell
2,906
-26,687
-90% -$2.39M ﹤0.01% 1077
2020
Q4
$2.79M Buy
29,593
+3,885
+15% +$339K 0.01% 410
2020
Q3
$2.24M Sell
25,708
-1,995
-7% -$173K 0.01% 420
2020
Q2
$2.42M Sell
27,703
-15,215
-35% -$1.31M 0.01% 371
2020
Q1
$3.54M Sell
42,918
-260
-0.6% -$23.2K 0.03% 281
2019
Q4
$4.09M Sell
43,178
-244
-0.6% -$21.9K 0.02% 292
2019
Q3
$3.77M Sell
43,422
-4,806
-10% -$432K 0.02% 299
2019
Q2
$4.4M Sell
48,228
-28,382
-37% -$2.4M 0.03% 268
2019
Q1
$6.6M Buy
76,610
+15,233
+25% +$1.22M 0.04% 194
2018
Q4
$4.72M Sell
61,377
-468
-0.8% -$36.4K 0.03% 202
2018
Q3
$4.78M Sell
61,845
-1,585
-2% -$117K 0.03% 230
2018
Q2
$4.29M Sell
63,430
-2,042
-3% -$141K 0.03% 245
2018
Q1
$4.74M Sell
65,472
-1,250
-2% -$95.2K 0.03% 226
2017
Q4
$5.02M Buy
66,722
+348
+0.5% +$26.3K 0.03% 221
2017
Q3
$5.11M Buy
+66,374
New +$5.01M 0.03% 216

Other funds holding NVS

CIBC Asset Management's NVS Position: Q1 2026 in Review

CIBC Asset Management increased its Novartis (NVS) stake by 4.9% in Q1 2026, buying an estimated $198K and bringing the position to 27,556 shares worth $4.17M. The position accounts for 0.01% of the portfolio, ranked #527.

CIBC Asset Management first reported a position in NVS in Q3 2017 and has held it in 24 quarters since. The position peaked at $6.6M in Q1 2019. 1,590 funds tracked by Wall St. Rank hold NVS as of Q1 2026.

  • CIBC Asset Management held 27,556 shares of Novartis worth $4.17M as of Q1 2026.
  • CIBC Asset Management bought 1,292 Novartis shares in Q1 2026, an estimated $198K.
  • Novartis made up 0.01% of CIBC Asset Management's portfolio in Q1 2026, its #527 holding.
  • CIBC Asset Management first reported a position in Novartis in Q3 2017 and has held it in 24 quarters since.
  • CIBC Asset Management's Novartis position peaked at $6.6M in Q1 2019.
  • 1,590 funds tracked by Wall St. Rank held Novartis as of Q1 2026.

Based on CIBC Asset Management's 13F filing for Q1 2026, filed 12 May 2026.